Treatment of Endometrial Atrophy
For symptomatic postmenopausal women with endometrial atrophy causing vulvovaginal symptoms, start with vaginal moisturizers used at least twice weekly, and if symptoms persist, escalate to low-dose vaginal estrogen therapy. 1
Stepwise Treatment Algorithm
First-Line: Non-Hormonal Management
For women with genitourinary symptoms related to endometrial atrophy:
- Vaginal moisturizers: Use at least twice weekly for ongoing symptom relief 1
- Vaginal lubricants: Add for women experiencing insufficient vaginal secretions during sexual activity 1
These non-hormonal options should be trialed first as they carry no systemic risks and provide adequate relief for many women.
Second-Line: Low-Dose Vaginal Estrogen Therapy
When non-hormonal therapies fail, low-dose vaginal estrogen is the recommended treatment for women without contraindications (no history of estrogen-dependent cancers) 1. This is a strong recommendation based on moderate-quality evidence.
Key Points About Vaginal Estrogen:
- No progestogen needed: When using low-dose vaginal estrogen, do not add a progestogen—there is no need for endometrial protection at these doses 1
- Forms available: Vaginal creams, tablets, or rings are equally effective with no significant differences in endometrial safety 1
- Safety profile: Studies up to 1 year show no cases of endometrial hyperplasia or cancer with low-dose vaginal estradiol 1
- Endometrial monitoring: The boxed FDA warning on cardiovascular and cancer risks does not apply to low-dose vaginal preparations 1
Alternative: Oral Ospemifene
For women who prefer oral medication or are uncomfortable with vaginal preparations:
- Ospemifene can be used for moderate to severe dyspareunia associated with vaginal atrophy 1
- Contraindications: Do NOT use in women with breast cancer history (strong recommendation) 1
- Risks: Increased VTE risk, endometrial thickening (60.1/1000 women-years vs 21.2/1000 with placebo), and vasomotor symptoms as side effect 1
Special Populations
Women with Cancer History
Breast or endometrial cancer survivors: If symptomatic and non-hormonal therapies fail, use shared decision-making with the treating oncologist before considering low-dose vaginal estrogen 1. This is particularly important for women on aromatase inhibitors, where even small estrogen increases could theoretically affect treatment efficacy 1.
Women on Raloxifene
For women taking raloxifene who develop genitourinary symptoms unresponsive to non-hormonal therapies, adding low-dose vaginal estrogen is appropriate 1.
Critical Safety Monitoring
Any postmenopausal bleeding or spotting in women using vaginal estrogen requires prompt evaluation for endometrial pathology (strong recommendation) 1. This is non-negotiable—do not attribute bleeding to the treatment without excluding malignancy.
For women at higher risk of endometrial cancer (late menopause, obesity, higher dosing), consider surveillance with transvaginal ultrasound followed by endometrial biopsy if thickening is present 1.
Important Clinical Pitfall
Do not assume endometrial atrophy is the cause of postmenopausal bleeding simply because biopsy shows atrophic histology 2. Atrophic endometrium is ubiquitous in postmenopausal women and is physiologic, not pathologic. Focal lesions causing bleeding are frequently missed by sampling and can harbor cancer. If a woman has postmenopausal bleeding with atrophic endometrium on pathology, perform transvaginal ultrasound—if endometrial thickness is present, further workup is mandatory to find the true bleeding source 3, 2.
Emerging Therapies
For refractory cases of severe endometrial atrophy (particularly Asherman's syndrome or thin endometrium affecting fertility), emerging regenerative approaches show promise but remain investigational:
- Platelet-rich plasma (PRP)
- Stem cell-based therapies (autologous bone marrow-derived stem cells have shown endometrial regeneration in small studies) 4, 5
- Bioengineering-based techniques 6, 5
These are not yet standard of care and require further clinical validation.